FDA Approves First Targeted Drug against Cystic Fibrosis

Image: Illustration by John Hendrix The U.S. Food and Drug Administration today approved a new drug that tackles the underlying cause of cystic fibrosis (CF) in 4 percent of patients . The drug, called ivacaftor (brand name Kalydeco), acts by helping the body make better use of a protein that works incorrectly in cystic fibrosis patients.

Read the original here:
FDA Approves First Targeted Drug against Cystic Fibrosis